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A B S T R A C T
In recent years, the delivery of osteoinductive factors such as bone morphogenic proteins (BMPs) has become an alter-
native approach to traditional bone grafting due to their capacity to produce bone healing and new bone formation.
BMP-2 has proved to possess the highest osteoinductive potential among BMPs. The case reported the clinical use of
recombinant human BMP-2 for bilateral vertical alveolar ridge augmentation. In a case of 61 year-old patient with a
significant bilateral vertical bony deficiency of the mandible, rhBMP-2 administered via an absorbable collagen sponge
carrier (ACS) was used for bilateral alveolar ridge bone induction. Augmented sites were covered and fixed with tita-
nium mesh. Augmented sites were reopened 6 months after surgery. Titanium membrane and retaining screws were
removed and three dental implants were placed. The tissue samples for the histologic analysis were harvested. Following
3 months healing period, the submerged implants were uncovered and restored with zirconium-ceramic crowns. Cone
beam computed tomography (CBCT), panoramix and 3D radiographic evaluation were obtained prior to and after the
surgical procedure. Vertical gain of the bone was 5.5 mm on the left and 5 mm on the right side, with 6 mm width of the
bone. Histologic analysis revealed formation of mature trabecular bone with signs of osteoblastic proliferation. Implant
stability quotient (ISQ) values were in the range between 69 and 75 for all three implants. No suppuration, gingival
recession or pain were present 24 months after surgery. Vertical bone augmentation using rhBMP-2 is optional treatment
modality to consider when planning dental implant placement in sites where severe vertical insufficiency exists.
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Introduction
Use of autogenous block grafts has long been accepted
as the gold standard for reconstruction of deficient alveo-
lar ridge dimension. However, its numerous risks, such
as pain, infection, and morbidity, combined with a limi-
ted quantity of available donor site tissue have led many
to employ alternative regenerative materials including
allografts, xenografts or synthetic materials. In recent
years, the delivery of osteoinductive factors such as bone
morphogenic proteins (BMPs) have become an alterna-
tive approach to traditional bone grafting due to their ca-
pacity to enhance the natural ability of the surrounding
tissues to produce bone healing and new bone forma-
tion1,2. BMP-s are members of the transforming growth
factor-b (TGF-b) family of proteins3. Their activity rela-
ted to bone induction remained unknown until 1988.
when first recombinant BMPs were cloned4, BMP-2 has
proved to possess the highest osteoinductive potential
among BMPs and thus plays an important role in the
early phase of proliferation and differentiation of me-
senchymal progenitor cells into osteoblasts5,6. Prior to
FDA approval, extensive preclinical and animal studies
were conducted to examine the efficacy and limitations
of BMP-2 in promoting bone formation7. Animal models
have demonstrated that fracture healing can be acceler-
ated by local administration of rhBMP-28,9. Most recently,
the effects of rhBMP-2 on the osseointegration of tita-
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nium implants have also been investigated in the experi-
mental animal studies. Basic clinical research showed
that newly formed bone is woven bone with vital osteo-
blasts and adequate vascularisation, thus representing a
favorable environment for implant placement2,10–13. The
safe application of rhBMP-2 has further been confirmed
in human studies14,15.
In this report, a case of clinical usage of rhBMP-2 for
bilateral alveolar ridge bone induction following dental
implants placement, was presented.
Case Report
A 61-year-old man was referred to the Department of
Oral Surgery University of Zagreb by his general dentist
for treatment of severe vertical bone deficiency in both
the mandibular molar regions (Figure 1). The patient’s
medical history was not contributory. CBCT and pano-
ramix mandibular scans were obtained preoperatively
and showed 5-6 mm of bone superior to the mandibular
canal which was insufficient to enable dental implant
placement without augmentation procedures (Figure 2a).
The patient underwent initial periodontal therapy prior
to surgery. A written consent was obtained by the patient
prior to surgical treatment.
A broad-spectrum antibiotic was administered preop-
eratively. Anesthesia was achieved via mandibular block
(Articaine 1:200000, 3M ESPE AG, Seefeld, Germany).
Full thickness horizontal incision was made along the
edentulous crest and extended intrasulcularly at the lin-
gual aspect of the mandibular premolars on each side. Ver-
tical releasing incisions, located at the mesio-buccal line
angles of the adjacent anterior teeth, were created to facil-
itate surgical access and tension-free flap closure. Bone
augmentation of the mandibular alveolar ridge was per-
formed using rhBMP-2 (1.5 mg/mL) in combination with
an absorbable collagen sponge (ACS) carrier (INFUSE®
Bone Graft, Medtronic Spinal and Biologics, Memphis,
TN, USA). 2.5 mL of the solution was applied to the car-
rier for treatment of the right side and 1.5 mL for the left
side, according to the manufacturer prescribed protocol.
Augmented sites were covered with a rigid titanium
membrane, 0.1 mm thick (Titanium Mesh, 25x30 mm,
Salvin, USA), and fixed using screws located in the antic-
ipated sites of the future dental implants. Two screws were
secured through the mesh to support the height of the al-
veolar ridge, and two tacks were also placed to secure the
edges to the native bone. Periostal releasing was done to
allow for passive primary closure using silk sutures
(Mersilk, 4/0, Ethicon, INC, New Jersey, USA). Moderate
edema and erythema were observed on day 2 following
surgery and persisted for 2 weeks. Sutures were removed
ten days after surgical procedure.
Six months after surgery, reopening of the augmented
sites were performed when the titanium membrane and
the stabilizing screws were removed (Figure 3). Newly
formed bone appeared immature, trabecular in appear-
ance and did not have a dense outer cortical layer in com-
parison to the adjacent native bone and felt soft in con-
sistency relative to the subjacent native bone when being
drilled during implant sites preparation. The osteoto-
mies for the implants placement were prepared through
previous screws sites following drilling with the trephine
due to harvesting regenerated bone samples for histolo-
gical analysis. Dental implants (NobelReplace™ Tapered
Groovy, Nobel Biocare AB,Göteborg, Sweden) were pla-
ced (Figure 3) in the sites 36 (4.3x13 mm), 46 (4.3x13
mm) and 47 (4.3x10 mm) and good primary stability was
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Fig. 1. Clinical findings in the 61-year-old patient pre-surgery and postoperatively.
achieved. The bone quality was evaluated by resonance
frequency device Osstell (Osstell AB, Goteborg, Sweden).
ISQ values were in the range between 73 and 76 for all
three implants. The surgical site was sutured using silk
sutures (Mersilk, 4/0, Ethicon, INC, New Jersey, USA).
Plaque control was maintained by daily rinses of the oral
cavity with 0.2% clorhexidine (Corsodyl, GlaxoSmith-
Kline, UK) and hyaluronic acid agent (Gengigel, Medis
Adria, Italy),which were used separately 3 times a day
until suture removal. Sutures were removed 10 days
post-surgery. Three months following implant place-
ment, second surgical phase was performed. Thin layer
of soft tissue of fibrous consistency was noted overlying
the surface of the regenerated bone which, when re-
moved, revealed bone overgrowing the top of the implant
cover screws. Healing abutments were placed for a pe-
riod of two weeks after which ceramic abutments were
placed on the implants, and finally restored with zirco-
nia-ceramic restorations.
CBCT radiographic evaluation was obtained prior to
and 1 month following dental implants placament, as
well as on the 24 month recall. Panoramics radiographs
were obtained prior to and 6 months following ridge aug-
mentation, and then at 12 and 24 months after implants
placamento (Figure 2). ISQ values were in the range be-
tween 69 and 74 for all three implants during follow-up
period of 12 months.
Histological analysis revealed the architecture of har-
vested bone tissue comprised of mainly lamellar bone
and smaller amount of woven bone (Figure 4). Woven
bone showed signs of trabecular remodelling as differen-
tiated by the pattern of osteoclasts and moderate osteo-
blastic proliferation. The newly formed bone was more
similar to trabecular bone typical of the maxilla and was
represented by higher percentage of bone marrow suo-
rounding bone fragments. Bone fragments with signs of
mechanically damaged structure (basophilic areas) were
randomly present in the medullary space with signs of
mechanical damage due to using the trephine drill. In-
flammatory cells were not present and bone voids were
not detected.
No suppuration, gingival recession, pain or ongoing
pathologic processes were present on the time of fol-
low-up 24 months after surgery.
D. Katanec et al.: Use of rhBMP2 in Alveolar Ridge Augmentation, Coll. Antropol. 38 (2014) 1: 325–330
327
Fig. 2. Radiographic evaluation. a) Panoramix prior to surgery representing significant vertical bony deficiency in both mandibular
right and left molar regions. b) Panoramix 3 months post surgery representing bone growing into space delineated by titanium membrane.
c) Panoramix 6 months post surgery representing significant bone growth into space delineated by titanium membrane. d) Panoramix
after placement of dental implants representing bone overgrowing the top of the implant cover screws. e) CBCT taken 12 months post
surgery representing vertical gain of newly formed bone.
Discussion
Several groups of authors showed in animal modesl
that rhBMP-2 induced bone formation accommodates
not only installation and osseointegration, but also long-
term functional loading of endosseous implants2,10–13.
Early rh-BMP use in humans was reported in case report
whereby reconstruction of a large mandibular resection
defect was done following removal of an ameloblastoma16.
The Food and Drug Administration approved rhBMP-2
for autograft replacement in spinal fusions in 2002, in
2004 for open tibia fractures, and in 2007 for sinus aug-
mentations, and for localized alveolar ridge defects,
when for the first time were used for reconstruction of
mandibular bone defects in humans17. Most of the au-
thors found several problems when using rhBMP-2 in
human surgical procedures. Some disadvantages of the
collagen carrier proved to be related to its lack of struc-
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Fig. 3. Second surgical procedure, removal oft he titanium mesh, sample for the histological analysis harvesting
and dental implants placement.
tural stability and inability to maintain space as it is
compressed by soft-tissues overlying the defect10–13. For
these reasons, current research attempts are directed to-
ward developing a matrix with more structural ability ca-
pable of maintaining the space for bone induction during
healing17. For this reason the treatment we presented in
this case report included the use of a pure titanium mem-
brane which was secured prior to placing the loading col-
lagen carrier as a means of creating a physical structure
to maintain space for regeneration to occur. Further-
more, rhBMP-2/ACS in the amount of 1.5 mg/cc was
used, which has been proved to be optimal for bone
augmentation7. Based on the comparison of two doses of
rhBMP-2/ACS (0.75 and 1.5 mg/cc) for treating post-ex-
traction defects, a higher dose seems to affect the
amount and velocity of the newly formed bone18. How-
ever, peri-implant bone remodelling and seroma forma-
tion has been observed to be considerably more extensive
and aggressive at a higher rhBMP-2 concentration10. The
results reported by Carter17, attributed some failures of
bone regenaration using rhBMP-2 due to infection. Doc-
umented adverse events linked to rhBMP-2 include bone
resorption or remodelling at the graft site, severe neck
swelling, hematoma, painful seroma, ectopic bone forma-
tion and severe dysphagia14-18. The most frequent com-
plication is edema, noted in our case as well, which may
occur partially due to fast releasing of of the full dose of
rhBMP-2 from ACS once being placed in the defect. A dis-
advantage of rhBMP-2/ACS is its half-time of approxi-
mately 7–16 minutes with a burst release within 1 hour
of implantation and lacks any controlled releasing prop-
erty. Further research is indicated to better understand
and determine optimal dose of rhBMP-2, timing of its re-
lease and carrier vehicle to yield predictable and reliable
bone regeneration.
Although the expectation was to gain approximatelly
8–9 mm of bone height, the final outcome was repre-
sented by gaining 5–5.5 mm of the newly formed bone in
the posterior mandible. Vertical gain of newly formed
bone was 5.5 mm on the left and 5 mm on the right side,
which was comparable with the similar results achieved
by using the conc. of 1.5 mg/cc in the case of sinus aug-
mentation, representing newly formed bone height of
7.83 mm and 9.46 mm respectively14. It could be also as-
sumed that the type of bone in the surgical site may af-
fect induction of the bone formation.
ISQ values, which in our study ranged from 69–76,were
comparable with the study of Alsabeeha19, in which the
ISQ values ranging between 75–85 acquired for the pos-
terior portion of the mandible presented the native bone
standard mesurement. The lower ISQ values were ob-
tained due to the type of newly formed bone induced by
rhBMP-2, rather than related to the implant site prepa-
ration.
Radiographic findings in our study revealed improved
density of newly formed bone, which in structure was
very similar to the native bone. These results contribute
to previous findings that rhBMP-2 induced bone contin-
ues maturing and by 12-24 weeks post implantation can-
not be radiogrhically differentiated from the resident
bone20. Radiolucent voids in rhBMP-2 induced bone have
been observed in mutiple studies utilizing a variety of
carriers in suprealveolar or saddle-type defects in dogs,
being detected as seromas or sterile accumulations of se-
rum in a circumscribed location20,21. However, no voids
were detected in our study, which is in accordance with
findings from other human reports following the use of
us rhBMP-222.
Conclusion
Vertical bone augmentation using rhBMP-2 is optional
treatment modality to consider when planning dental im-
plant placement in sites where severe vertical insufficien-
cy exists. However, further research is indicated to better
understand and determine optimal dose of rhBMP-2, tim-
ing of its release and carrier vehicle to yield predictable
and reliable bone regeneration.
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UPOTREBA REKOMBINATNOG HUMANOG MORFOGENETSKOG PROTEINA (rhBMP-2)
U OBOSTRANOJ AUGMENTACIJI ALVEOLARNOG GREBENA – PRIKAZ SLU^AJA
S A @ E T A K
U posljednjih nekoliko godina upotreba oseoinduktivnih faktora rasta kao {to su BMP-i, postali su alternativni izbor
u odnosu na tradicionalnom ko{tanom presa|ivanju zbog svoje sposobnosti formiranja novog ko{tanog tkiva. Najve}i
oseoinduktivni potencijal me|u BMP pokazuje BMP-2. U ovom prikazu slu~aja prikazujemo upotrebu rekombinatnog
humanog BMP-2 (rhBMP-2) u kombinaciji sa kolagenom spu`vicom za obostranu vertikalnu augmentaciju alveolarnog
grebena kod pacijenta starog 61 godinu sa zna~ajnim obostranim vertikalnim nedostatkom kosti u donjoj ~eljusti.
Augmentacijska mjesta su prekrivena i fiksirana titanskom mre`icom. 6 mjeseci nakon augmentacije titanska mre`ica
je uklonjena i na njenom mjestu su postavljena 3 dentalna implantata. Prilikom preparacije le`i{ta implantata uzet je
dio novostvorenog tkiva za histolo{ku analizu. Nakon tromjese~nog perioda cijeljenja postavljene su cirkon-kerami~ke
krunice. CBCT i panoramske snimke su poslikane prije i nakon opracije. Vertiklani dobitak kosti je bio 5,5 mm za lijevu
i 5 mm za desnu stranu donje ~eljusti sa {irinom od 6 mm. Histolo{ka analiza je pokazala formiranje zrele spu`vaste
kosti sa znakovima proliferacije osteoblasta. ISQ vrijednosti su u rasponu od 69 do 75 za sva tri implantata. Nakon 24
mjeseci nije opisane nikakve komplikacije u vidu gnojenja, recesije ili boli. Vertiklana augmentacija pomo}u rhBMP-2
mo`e se uzeti u obzir za lije~enje ve}ih vertikalnih ko{tanih insuficijencija prije implantoprotetske rehabilitacije.
